Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.

O'Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ.

Gynecol Oncol. 2019 Dec;155(3):393-399. doi: 10.1016/j.ygyno.2019.09.015. Epub 2019 Oct 22.

PMID:
31653510
2.

Dual Actions of Ketorolac in Metastatic Ovarian Cancer.

Hudson LG, Cook LS, Grimes MM, Muller CY, Adams SF, Wandinger-Ness A.

Cancers (Basel). 2019 Jul 24;11(8). pii: E1049. doi: 10.3390/cancers11081049. Review.

3.

Innovation and Progress in Gynecologic Cancer Care: Faster than Ever.

Muller CY.

Obstet Gynecol Clin North Am. 2019 Mar;46(1):xv-xvi. doi: 10.1016/j.ogc.2018.11.001. No abstract available.

PMID:
30683270
4.
5.

Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer.

Winner KK, Steinkamp MP, Lee RJ, Swat M, Muller CY, Moses ME, Jiang Y, Wilson BS.

Cancer Res. 2016 Mar 15;76(6):1320-1334. doi: 10.1158/0008-5472.CAN-15-1620. Epub 2015 Dec 30.

6.

Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.

Brooks SE, Muller CY, Robinson W, Walker EM, Yeager K, Cook ED, Friedman S, Somkin CP, Brown CL, McCaskill-Stevens W.

J Oncol Pract. 2015 Nov;11(6):486-90. doi: 10.1200/JOP.2015.005934. Epub 2015 Oct 13.

7.

R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.

Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A.

Mol Cancer Ther. 2015 Oct;14(10):2215-27. doi: 10.1158/1535-7163.MCT-15-0419. Epub 2015 Jul 23.

8.

A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.

Guo Y, Kenney SR, Cook L, Adams SF, Rutledge T, Romero E, Oprea TI, Sklar LA, Bedrick E, Wiggins CL, Kang H, Lomo L, Muller CY, Wandinger-Ness A, Hudson LG.

Clin Cancer Res. 2015 Nov 15;21(22):5064-72. doi: 10.1158/1078-0432.CCR-15-0461. Epub 2015 Jun 12.

9.

Summary of the 45th annual meeting on women's cancers.

Olawaiye AB, Muller CY.

Gynecol Oncol. 2014 Jun;133(3):394-7. No abstract available.

PMID:
25006644
10.

High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.

Davies S, Holmes A, Lomo L, Steinkamp MP, Kang H, Muller CY, Wilson BS.

Int J Gynecol Pathol. 2014 Jul;33(4):402-10. doi: 10.1097/PGP.0000000000000081.

11.

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK.

Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4.

12.

Investigation of mammographic breast density as a risk factor for ovarian cancer.

Wernli KJ, O'Meara ES, Kerlikowske K, Miglioretti DL, Muller CY, Onega T, Sprague BL, Henderson LM, Buist DS.

J Natl Cancer Inst. 2014 Jan;106(1):djt341. doi: 10.1093/jnci/djt341. Epub 2013 Dec 5.

13.

A pilot randomized control trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors.

Rutledge TL, Rogers R, Lee SJ, Muller CY.

Gynecol Oncol. 2014 Jan;132(1):154-8. doi: 10.1016/j.ygyno.2013.10.024. Epub 2013 Oct 29.

14.

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F.

Ann Oncol. 2012 Dec;23(12):3104-3110. doi: 10.1093/annonc/mds172. Epub 2019 Dec 4.

PMID:
32018816
15.

Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites.

Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL.

Cancer Causes Control. 2013 Jan;24(1):61-9. doi: 10.1007/s10552-012-0090-z. Epub 2012 Oct 30.

16.

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F.

Ann Oncol. 2012 Dec;23(12):3104-10. doi: 10.1093/annonc/mds172. Epub 2012 Jul 31.

17.

I grew up watching the original Star Trek, amazed at the level of medical technology utilized in many episodes. Introduction.

Muller CY.

Obstet Gynecol Clin North Am. 2012 Jun;39(2):xv-xvi. doi: 10.1016/j.ogc.2012.04.003. No abstract available.

PMID:
22640718
18.

Drug Repurposing from an Academic Perspective.

Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, Jarvik JW, Gresham HD, Haynes MK, Hjelle B, Hromas R, Hudson L, Mackenzie DA, Muller CY, Reed JC, Simons PC, Smagley Y, Strouse J, Surviladze Z, Thompson T, Ursu O, Waller A, Wandinger-Ness A, Winter SS, Wu Y, Young SM, Larson RS, Willman C, Sklar LA.

Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):61-69.

19.

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

Ann Oncol. 2012 Mar;23(3):785-790. doi: 10.1093/annonc/mdr299. Epub 2019 Dec 4.

PMID:
32018677
20.

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML.

Gynecol Oncol. 2012 Jan;124(1):48-52. doi: 10.1016/j.ygyno.2011.09.019. Epub 2011 Oct 13.

21.

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11.

22.

A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J.

Int J Gynecol Cancer. 2010 Oct;20(7):1137-41.

23.

Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study.

Rutledge TL, Heckman SR, Qualls C, Muller CY, Rogers RG.

Am J Obstet Gynecol. 2010 Nov;203(5):514.e1-7. doi: 10.1016/j.ajog.2010.08.004. Epub 2010 Sep 24.

24.

Analysis of genetic copy number changes in cervical disease progression.

Policht FA, Song M, Sitailo S, O'Hare A, Ashfaq R, Muller CY, Morrison LE, King W, Sokolova IA.

BMC Cancer. 2010 Aug 16;10:432. doi: 10.1186/1471-2407-10-432.

25.

Doctor, should I get this new ovarian cancer test-OVA1?

Muller CY.

Obstet Gynecol. 2010 Aug;116(2 Pt 1):246-7. doi: 10.1097/AOG.0b013e3181e934ba. No abstract available.

PMID:
20664381
26.

USA hCG reference service, 10-year report.

Cole LA, Laidler LL, Muller CY.

Clin Biochem. 2010 Aug;43(12):1013-22. doi: 10.1016/j.clinbiochem.2010.05.006. Epub 2010 May 21.

PMID:
20493830
27.

Targeting the EGF receptor for ovarian cancer therapy.

Zeineldin R, Muller CY, Stack MS, Hudson LG.

J Oncol. 2010;2010:414676. doi: 10.1155/2010/414676. Epub 2009 Dec 28.

28.

Normal production of human chorionic gonadotropin in perimenopausal and menopausal women and after oophorectomy.

Cole LA, Khanlian SA, Muller CY.

Int J Gynecol Cancer. 2009 Dec;19(9):1556-9.

PMID:
19994471
29.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE.

J Clin Oncol. 2010 Jan 1;28(1):149-53. doi: 10.1200/JCO.2009.24.1455. Epub 2009 Nov 16.

30.

Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases.

Cole LA, Muller CY.

Gynecol Oncol. 2010 Jan;116(1):3-9. doi: 10.1016/j.ygyno.2009.09.028. Epub 2009 Oct 12.

PMID:
19822356
31.

The quagmire of hCG and hCG testing in gynecologic oncology.

Muller CY, Cole LA.

Gynecol Oncol. 2009 Mar;112(3):663-72. doi: 10.1016/j.ygyno.2008.09.030. Epub 2008 Nov 12.

PMID:
19007977
32.

Pelvic masses.

Barney SP, Muller CY, Bradshaw KD.

Med Clin North Am. 2008 Sep;92(5):1143-61, xi. doi: 10.1016/j.mcna.2008.04.007. Review.

PMID:
18721656
34.

Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm.

Cole LA, Khanlian SA, Muller CY.

Am J Obstet Gynecol. 2008 Mar;198(3):275.e1-7. doi: 10.1016/j.ajog.2007.09.034.

PMID:
18313448
35.

Absence of epidermal growth factor receptor mutations in cervical cancer.

Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54. Epub 2007 Oct 19.

PMID:
17949425
36.

Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.

Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, Muller CY.

Reprod Sci. 2007 Jan;14(1):20-8.

PMID:
17636212
37.

Normal production of human chorionic gonadotropin in menopause.

Cole LA, Sasaki Y, Muller CY.

N Engl J Med. 2007 Mar 15;356(11):1184-6. No abstract available.

PMID:
17361004
38.

Changing trends in gestational trophoblastic disease.

Smith HO, Wiggins C, Verschraegen CF, Cole LW, Greene HM, Muller CY, Qualls CR.

J Reprod Med. 2006 Oct;51(10):777-84.

PMID:
17086806
39.

Incidence and survival rates for female malignant germ cell tumors.

Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR.

Obstet Gynecol. 2006 May;107(5):1075-85.

PMID:
16648414
40.

Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a reliable marker of placental site trophoblastic tumors.

Cole LA, Khanlian SA, Muller CY, Giddings A, Kohorn E, Berkowitz R.

Gynecol Oncol. 2006 Aug;102(2):160-4. Epub 2006 May 2.

PMID:
16631918
41.

Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.

Cole LA, Khanlian SA, Giddings A, Butler SA, Muller CY, Hammond C, Kohorn E.

Gynecol Oncol. 2006 Aug;102(2):165-72. Epub 2006 May 2.

PMID:
16631243
42.

Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia.

Cole LA, Butler SA, Khanlian SA, Giddings A, Muller CY, Seckl MJ, Kohorn EI.

Gynecol Oncol. 2006 Aug;102(2):151-9. Epub 2006 May 2.

PMID:
16631241
43.

Cervical neoplasia complicating pregnancy.

Muller CY, Smith HO.

Obstet Gynecol Clin North Am. 2005 Dec;32(4):533-46. Review.

PMID:
16310670
44.

A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis.

Rao GG, Kurien A, Gossett D, Griffith WF, Coleman RL, Muller CY.

Gynecol Oncol. 2006 May;101(2):250-4. Epub 2005 Nov 17.

PMID:
16297972
45.

Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix.

Castle PE, Ashfaq R, Ansari F, Muller CY.

Cancer Lett. 2005 Nov 18;229(2):245-52. Epub 2005 Aug 19.

PMID:
16112431
46.

BRCAPAP: feasibility of clinical BRCA testing on liquid-based cervical cytology: implications for biomarker development.

Muller CY, Schorge JO, Tomlinson GE, Ashfaq R.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1534-7.

47.

Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.

Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY.

J Soc Gynecol Investig. 2004 Jul;11(5):329-37.

PMID:
15219888
48.

The miracle of life and privilege of death.

Muller CY.

Obstet Gynecol. 2004 Jun;103(6):1314-6. No abstract available.

PMID:
15172870
49.

CCND1 polymorphism and age of onset of hepatoblastoma.

Pakakasama S, Chen TT, Frawley W, Muller CY, Douglass EC, Lee R, Pollock BH, Tomlinson GE.

Oncogene. 2004 Jun 10;23(27):4789-92.

PMID:
15133490
50.

Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.

Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY.

Am J Obstet Gynecol. 2004 Mar;190(3):674-9.

PMID:
15041998

Supplemental Content

Loading ...
Support Center